



Pergamon

Tetrahedron Letters 40 (1999) 5593–5596

TETRAHEDRON
LETTERS

Enantioselective synthesis of senecivernine, a 12-membered dilactonic pyrrolizidine alkaloid

Zhi-Yu Liu * and Lian-Yun Zhao


Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Lu, Shanghai 200032, China

Received 6 April 1999; accepted 25 May 1999

Abstract

The first synthesis of the title compound is described using a rigid molecule tricyclodecadienone **8** as the starting material and a retro-Diels–Alder reaction as the key step for the efficient synthesis of a masked seneciverinic acid **20**; the target was prepared using the esterification of two hydroxy groups of (+)-retronecine **7** sequentially with compound **20** in a total of 19 steps and 18% overall yield. © 1999 Elsevier Science Ltd. All rights reserved.

12-Membered dilactonic pyrrolizidine alkaloids have attracted much attention due to their interesting chemical structure and unique biological activities.^{1,2} Three members, integerrimine **1**,^{3–5} its 15,18-dihydroderivative, yamataimine⁶ and usaramine **2**⁵ have been synthesized (Scheme 1).




Scheme 1.

Senecivernine **3** was isolated from *Senecio vernalis* Walkstein et Kit by the Roder group⁷ in 1979 and its full stereochemistry, showing the same stereochemistry as that in compounds merenskine **4**⁹ and sceleratine **5**,¹⁰ was recently determined with X-ray analysis by Parvez.⁸ Therefore, senecivernine **3** might be a biogenetic precursor of merenskine **4** and sceleratine **5** even though the corresponding epoxide of senecivernine **3** has not been isolated from nature. In comparison with integerrimine **1** and

* Corresponding author.

usaramine **2**, senecivernine **3** has an additional chiral center at C₁₄ and a more sensitive *exo*-methylene group at C₁₅, which is an important moiety in many natural products responsible for antitumor activity. This distinct feature greatly arouses our interest in the possible biological activity of senecivernine **3** and a total synthesis should be highly significant.

A major point for the synthesis of the pyrrolizidine alkaloid senecivernine **3** is the development of efficient methodologies for the introduction of all functional groups in a fully functionalized compound, and in the manner for the coupling of the necic base, a dihydroxy alkaloid (+)-retronecine **7** with the dicarboxylic acid **6** under mild conditions, during which the labile *exo*-methylene group in compound **6** would survive. During the course of our program in natural products synthesis by retro-Diels–Alder reaction,^{11–15} a rigid tricyclo[5.2.1.0^{2,6}]deca-4,8-dien-3-one **8** was used as a starting material for stereospecific introduction of the necessary functional groups and substituents, then retro-Diels–Alder reaction released a cyclopentenone derivative, which was a suitable precursor for the natural product synthesis. We now describe using this methodology for the first stereospecific synthesis of the title compound (Scheme 2).



Scheme 2. Reagents and conditions: (a) 4.0 equiv. CH₃Li, 2.0 equiv. CuI, THF, -78~ -60°C, 6 h, 94.4%; (b) CH₃OCO₂CH₃, NaH, 50–60°C, 8 h, 99%; (c) CH₃I, CH₂Cl₂, 10% NaOH, cat. Bu₄NI, rt, 30 h, 95%; (d) 410°C, 310 torr, 100%; (e) 4.0 equiv. CH₃Li, 2.0 equiv. CuI, 4 Å molecular sieves, THF, -78°C, 4 h, 95%; (f) 1.3 equiv. *m*-CPBA, cat. Li₂CO₃, CH₂Cl₂, reflux, 16 h, **14** (71%), **15** (8.6%); (g) 2.0 equiv. LDA, THF, -78°C, HMPA, HCHO(g), -45°C, 3 h; (h) Ac₂O, Et₃N, DMAP, CH₂Cl₂, rt, 10 h; (i) DBU, CH₂Cl₂, rt, 24 h, 81.4% from **13**; (j) 1.2 equiv. LiOH, THF:H₂O (1:1), 0°C, 8 h, 91.4%; (k) 2.0 equiv. DCC, 1.5 equiv. 2-trimethylsilylethanol, cat. amount DMAP, CH₂Cl₂, 0°C, overnight, 83%; (l) 2.0 equiv. LiOH, H₂O₂ THF/H₂O, 0°C, overnight, 82%; (m) (I) 3.4 equiv. TBS-OTf, 6.8 equiv. 2,6-lutidine, CH₂Cl₂, 0°C, 1 h; (II) K₂CO₃, MeOH:THF:H₂O (3:1:1), 25°C, 3 h, 99%; (n) (I) 3.0 equiv. Et₃N, 1.5 equiv. (EtO)₂P(O)Cl, THF, rt, 3 h; (II) 1.5 equiv. **7b**, cat. amount DMAP, 1.5 equiv. CH₃Li, THF, rt, 15 h, 86%; (o) 50 equiv. NH₄F, MeOH:H₂O (3:1), 60–65°C, 4 h, 93%; (p) 2.0 equiv. MsCl, 2.3 equiv. Et₃N, CH₂Cl₂, 0°C, 30 min; (q) 14 equiv. *n*-Bu₄NF, THF, 2 h, 93% from **21**; (r) 40% HF, CH₃CN, reflux, 6 h, 80%

1,4-Addition of lithium dimethyl cuprate to (-)-**8**¹⁶ gave exclusively *exo*-product **9**. A methoxycarbonyl group was introduced at the less hindered α-position of the carbonyl with dimethyl carbonate

in the presence of excess sodium hydride to afford **10**. In order to minimize the formation of *O*-methylated product, phase transfer methylation was chosen to produce the *exo*-methylated product **11** (91.8%) with a small amount of the corresponding *O*-methylated compound (6.7%). Retro-Diels–Alder reaction was accomplished by thermolysis of **11** at 410°C/340 torr to give the cyclopentenone **12**. β -Methyl controlled 1,4-addition of lithium dimethyl cuprate to **12** produced **13** and a small amount of an isomer **13a**, which could not be isolated by flash chromatography. Fortunately, Baeyer–Villiger oxidation of the above mixture provided isolable **14** (71%) and **15** (8.3%). Reaction of the enolate generated by treatment of **14** with LDA at –78°C, with formaldehyde in THF in the presence of HMPA introduced a hydroxymethyl group, which was then directly acetylated and treated with DBU at room temperature to give methylene lactone **16**. Selective hydrolysis of **16** produced a monoacid **17**, which condensed with 2-trimethylsilylethanol to give the lactone **18**. Carefully opening the lactone **18** with base provided the hydroxy acid **19**, which was treated with *t*-butyl-dimethylsilyltriflate and then selectively hydrolyzed to the desired monoacid **20**. The carboxylic acid in **20** was activated as its acyl phosphate and condensed with the lithium alkoxide of **7b**¹⁷ to give the ester **21**. The primary hydroxy silylether was selectively cleaved under mild conditions to give the alcohol **22**, which was unstable and used directly for the next step without purification. Mesylation of the alcohol **22** and selective cleavage of the trimethylsilylated ester with spontaneous macrolactonization produced dilactone **23**. Finally, removal of the silyl protecting group gave the target molecule **3**, which was identical with data reported by the Roder group⁷ by comparison of the spectroscopic data.¹⁸ Therefore, we have finished the first enantioselective synthesis of the highly functionalized 12-membered dilactone pyrrolizidine alkaloid senecivermine **3** from tricyclodecadienone **8** in 19 steps and 18% overall yield.

Acknowledgements

This project was supported by the Natural Sciences Foundation of China.

References

1. Part XVII on natural products synthesis by Retro-Diels–Alder reaction; for Part XVI, see: Liu, Z.-Y.; Chu, X.-J. *Tetrahedron* **1998**, *54*, 12561–12570.
2. (a) Mattocks, A. R. *Chemistry and Toxicology of Pyrrolizidine Alkaloids*; Academic Press: London, 1986. (b) White, J. D.; Amedio Jr., J. C.; Hrcniar, P.; Lee, N. C.; Ohira, S.; Yokochi, A. F. T. *Chem. Commun.* **1998**, 603–604.
3. (a) Narasaka, K.; Sakakura, T.; Uchimar, T.; Morimoto, K.; Mukaiyama, T. *Chem. Lett.* **1982**, 455–458. (b) Narasaka, K.; Sakakura, T.; Uchimar, T.; Guedin-Vuong, D. *J. Am. Chem. Soc.* **1984**, *106*, 2954–2961.
4. Niwa, H.; Miyachi, Y.; Okamoto, O.; Uosaki, Y.; Kuroda, A.; Ishiwata, H.; Yamada, K. *Tetrahedron* **1992**, *48*, 393–412.
5. White, J. D.; Amedio Jr., J. C.; Gut, S.; Ohira, S.; Jayasinghe, L. R. *J. Org. Chem.* **1992**, *57*, 2270–2284 and references cited therein.
6. Niwa, H.; Kunitani, K.; Nagoya, T.; Yamada, K. *Bull. Chem. Soc. Jpn.* **1994**, *67*, 3094–3099.
7. Roder, E.; Wiedenfeld, H.; Pastewka, U. *Planta Med.* **1979**, *37*, 131–136.
8. Parvez, M.; Benn, M. H. *Acta Cryst.* **1995**, *C51*, 1202–1204.
9. Bredenkamp, M. W.; Wiechers, A.; Van Rooyen, P. H. *Tetrahedron Lett.* **1985**, *26*, 929–932.
10. Bredenkamp, M. W.; Wiechers, A. *Tetrahedron Lett.* **1985**, *26*, 5721–5724.
11. Liu, Z.-Y.; Chu, X.-J. *Tetrahedron Lett.* **1993**, *34*, 349–352.
12. (a) Liu, Z.-Y.; He, L.; Zheng, H. *Synlett* **1993**, 191–192. (b) Liu, Z.-Y.; Chu, X.-J.; He, L.; Xie, Y.-N.; Zhao, L.-Y. *YOUJI HUAXUE* **1997**, *17*, 62–65 (English).
13. Liu, Z.-Y.; Dong, H.; Chu, X.-J. *Tetrahedron* **1994**, *43*, 12337–12348.
14. Chu, X.-J.; Dong, H.; Liu, Z.-Y. *Tetrahedron* **1995**, *44*, 173–180.
15. Liu, Z.-Y.; Zhao, L.-Y.; Xie, Y.-N.; Wu, Y.; Wong, L.-L.; Zheng, H. *J. Chem. Soc., Perkin Trans. 1* **1998**, 2127–2129.

16. (a) Zhang, L.; Yang, J.-Y.; Liu, Z.-Y. *Chinese Chem. Lett.* **1992**, *3*, 787-788 (English). (b) Liu, Z.-Y.; He, L.; Zheng, H. *Tetrahedron: Asymmetry* **1993**, *4*, 2277-2278.
17. White, J. D.; Ohira, S. *J. Org. Chem.* **1986**, *51*, 5492-5494.
18. **3**: m.p. 106-108°C; $[\alpha]_D^{23} = -34.2$ (c 0.5 in ethanol) (lit⁷ m.p. 103-105°C; $[\alpha]_D^{20} = -34.9$ (in ethanol)); IR (neat): $\nu = 3522, 2928, 1720$ (brs), 1633, 1453, 1257, 1166, 1131, 950 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): $\delta = 0.85$ (d, $J = 7.1$ Hz, 3H, CH₃), 1.08 (d, $J = 7.0$ Hz, 3H, CH₃), 1.33 (s, 3H, CH₃), 1.60-1.79 (m, $J = 1.5, 7.1$ Hz, 1H, CH), 2.01-2.31 (m, 1H, CH₂), 2.35-2.50 (m, 1H, CH₂), 2.50-2.60 (m, 1H, CH), 2.60-2.75 (m, 1H, CH₂) 3.15 (m, 1H, OH), 3.28 (m, 1H, CH₂), 3.39 (dd, $J = 1.8, 6.0$ Hz, 1H, CH₂), 3.97 (dd, $J = 1.8, 6.0$ Hz, 1H, CH₂), 4.07 (dd, $J = 0.7, 11.5$ Hz, 1H, CH₂), 4.35 (m, 1H, CH), 5.07 (dt, $J = 1.1, 3.8$ Hz, 1H, CH), 5.23 (s, 1H, CH₂=), 5.51 (d, $J = 11.7$ Hz, 1H, CH₂), 5.85 (s, 1H, CH₂=), 6.21 (m, 1H, -CH=); ¹³C NMR (75 MHz, CDCl₃): $\delta = 5.8, 12.1, 26.3, 34.3, 36.0, 40.8, 53.2, 60.8, 62.6, 75.6, 77.5, 77.8, 120.8, 131.5, 136.3, 147.5, 169.0, 178.4$; MS (70 eV): m/z (%): 336 (14) [M⁺+1], 291 (7.3) [M⁺-CO₂], 248 (15) [M⁺-CO₂-CH₃CO], 220 (31) [M⁺-CO₂-CH₃CO-C₂H₄], 120 (100) [C₈H₁₀N].